Placenta growth factor is over-expressed and has prognostic value in human breast cancer

Christian Parr, Gareth Watkins, Mike Boulton, Jun Cai, Wen G. Jiang

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

Placenta growth factor (PlGF) belongs to the vascular endothelial growth factor (VEGF) family, a group of angiogenic factors that are crucial for tumour angiogenesis. Very little is known about the significance of PlGF in human cancer. We hypothesise that PlGF may have a potent influence in breast cancer. This study examined PlGF levels in human breast cancer in relation to patient's clinical parameters. PlGF expression and distribution was examined quantitatively using real-time quantitative polymerase chain reaction (Q-PCR) on a cohort of human breast cancer tissue (n = 119) and background breast tissue (n = 33), qualitatively using reverse transcriptase polymerase chain reaction (RT-PCR) on a range of cell lines, and immunohistochemically on patient samples. All these techniques revealed that PlGF expression was dramatically increased (P = 0.028) in breast cancer tissues compared with normal breast tissue. We demonstrate that PlGF displays prognostic value through analysis of patient survival status (6-year follow-up), as elevated levels of PlGF were significantly associated (P = 0.017) with recurrence, metastasis and patient mortality. Our study has shown that PlGF is over-expressed in breast cancer tissues and correlates with patient prognosis, and is likely to play a major role in the pathogenesis of tumours.

Original languageEnglish (US)
Pages (from-to)2819-2827
Number of pages9
JournalEuropean Journal of Cancer
Volume41
Issue number18
DOIs
StatePublished - Dec 2005
Externally publishedYes

Fingerprint

Breast Neoplasms
Breast
Placenta Growth Factor
Angiogenesis Inducing Agents
Survival Analysis
Reverse Transcriptase Polymerase Chain Reaction
Vascular Endothelial Growth Factor A
Real-Time Polymerase Chain Reaction
Neoplasms
Neoplasm Metastasis
Recurrence
Cell Line
Mortality

Keywords

  • Angiogenesis
  • Breast cancer
  • Immunohistochemistry
  • Placenta growth factor
  • Prognosis
  • Real-time quantitative polymerase chain reaction
  • Vascular endothelial growth factor
  • Vascular endothelial growth factor receptor-1

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Placenta growth factor is over-expressed and has prognostic value in human breast cancer. / Parr, Christian; Watkins, Gareth; Boulton, Mike; Cai, Jun; Jiang, Wen G.

In: European Journal of Cancer, Vol. 41, No. 18, 12.2005, p. 2819-2827.

Research output: Contribution to journalArticle

Parr, Christian ; Watkins, Gareth ; Boulton, Mike ; Cai, Jun ; Jiang, Wen G. / Placenta growth factor is over-expressed and has prognostic value in human breast cancer. In: European Journal of Cancer. 2005 ; Vol. 41, No. 18. pp. 2819-2827.
@article{36533d82584442c0aaa45c6a1bfdcb9e,
title = "Placenta growth factor is over-expressed and has prognostic value in human breast cancer",
abstract = "Placenta growth factor (PlGF) belongs to the vascular endothelial growth factor (VEGF) family, a group of angiogenic factors that are crucial for tumour angiogenesis. Very little is known about the significance of PlGF in human cancer. We hypothesise that PlGF may have a potent influence in breast cancer. This study examined PlGF levels in human breast cancer in relation to patient's clinical parameters. PlGF expression and distribution was examined quantitatively using real-time quantitative polymerase chain reaction (Q-PCR) on a cohort of human breast cancer tissue (n = 119) and background breast tissue (n = 33), qualitatively using reverse transcriptase polymerase chain reaction (RT-PCR) on a range of cell lines, and immunohistochemically on patient samples. All these techniques revealed that PlGF expression was dramatically increased (P = 0.028) in breast cancer tissues compared with normal breast tissue. We demonstrate that PlGF displays prognostic value through analysis of patient survival status (6-year follow-up), as elevated levels of PlGF were significantly associated (P = 0.017) with recurrence, metastasis and patient mortality. Our study has shown that PlGF is over-expressed in breast cancer tissues and correlates with patient prognosis, and is likely to play a major role in the pathogenesis of tumours.",
keywords = "Angiogenesis, Breast cancer, Immunohistochemistry, Placenta growth factor, Prognosis, Real-time quantitative polymerase chain reaction, Vascular endothelial growth factor, Vascular endothelial growth factor receptor-1",
author = "Christian Parr and Gareth Watkins and Mike Boulton and Jun Cai and Jiang, {Wen G.}",
year = "2005",
month = "12",
doi = "10.1016/j.ejca.2005.07.022",
language = "English (US)",
volume = "41",
pages = "2819--2827",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "18",

}

TY - JOUR

T1 - Placenta growth factor is over-expressed and has prognostic value in human breast cancer

AU - Parr, Christian

AU - Watkins, Gareth

AU - Boulton, Mike

AU - Cai, Jun

AU - Jiang, Wen G.

PY - 2005/12

Y1 - 2005/12

N2 - Placenta growth factor (PlGF) belongs to the vascular endothelial growth factor (VEGF) family, a group of angiogenic factors that are crucial for tumour angiogenesis. Very little is known about the significance of PlGF in human cancer. We hypothesise that PlGF may have a potent influence in breast cancer. This study examined PlGF levels in human breast cancer in relation to patient's clinical parameters. PlGF expression and distribution was examined quantitatively using real-time quantitative polymerase chain reaction (Q-PCR) on a cohort of human breast cancer tissue (n = 119) and background breast tissue (n = 33), qualitatively using reverse transcriptase polymerase chain reaction (RT-PCR) on a range of cell lines, and immunohistochemically on patient samples. All these techniques revealed that PlGF expression was dramatically increased (P = 0.028) in breast cancer tissues compared with normal breast tissue. We demonstrate that PlGF displays prognostic value through analysis of patient survival status (6-year follow-up), as elevated levels of PlGF were significantly associated (P = 0.017) with recurrence, metastasis and patient mortality. Our study has shown that PlGF is over-expressed in breast cancer tissues and correlates with patient prognosis, and is likely to play a major role in the pathogenesis of tumours.

AB - Placenta growth factor (PlGF) belongs to the vascular endothelial growth factor (VEGF) family, a group of angiogenic factors that are crucial for tumour angiogenesis. Very little is known about the significance of PlGF in human cancer. We hypothesise that PlGF may have a potent influence in breast cancer. This study examined PlGF levels in human breast cancer in relation to patient's clinical parameters. PlGF expression and distribution was examined quantitatively using real-time quantitative polymerase chain reaction (Q-PCR) on a cohort of human breast cancer tissue (n = 119) and background breast tissue (n = 33), qualitatively using reverse transcriptase polymerase chain reaction (RT-PCR) on a range of cell lines, and immunohistochemically on patient samples. All these techniques revealed that PlGF expression was dramatically increased (P = 0.028) in breast cancer tissues compared with normal breast tissue. We demonstrate that PlGF displays prognostic value through analysis of patient survival status (6-year follow-up), as elevated levels of PlGF were significantly associated (P = 0.017) with recurrence, metastasis and patient mortality. Our study has shown that PlGF is over-expressed in breast cancer tissues and correlates with patient prognosis, and is likely to play a major role in the pathogenesis of tumours.

KW - Angiogenesis

KW - Breast cancer

KW - Immunohistochemistry

KW - Placenta growth factor

KW - Prognosis

KW - Real-time quantitative polymerase chain reaction

KW - Vascular endothelial growth factor

KW - Vascular endothelial growth factor receptor-1

UR - http://www.scopus.com/inward/record.url?scp=28244448600&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28244448600&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2005.07.022

DO - 10.1016/j.ejca.2005.07.022

M3 - Article

C2 - 16275058

AN - SCOPUS:28244448600

VL - 41

SP - 2819

EP - 2827

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 18

ER -